Stryker Corp. (NYSE:SYK) Director Ronda E. Stryker sold 18,000 shares of the company’s stock in a transaction dated Tuesday, October 11th. The stock was sold at an average price of $116.41, for a total transaction of $2,095,380.00. Following the completion of the transaction, the director now owns 193,142 shares in the company, valued at $22,483,660.22. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of Stryker Corp. (NYSE:SYK) opened at 113.73 on Wednesday. The firm has a market cap of $42.57 billion, a PE ratio of 26.81 and a beta of 0.72. The stock’s 50 day moving average is $115.18 and its 200-day moving average is $114.05. Stryker Corp. has a 52 week low of $86.68 and a 52 week high of $123.55.

Stryker Corp. (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 21st. The medical technology company reported $1.39 EPS for the quarter, topping the Zacks’ consensus estimate of $1.37 by $0.02. Stryker Corp. had a return on equity of 23.61% and a net margin of 15.33%. The business earned $2.84 billion during the quarter, compared to the consensus estimate of $2.79 billion. On average, equities analysts predict that Stryker Corp. will post $5.76 EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Stryker Corp. (NYSE:SYK)

The business also recently disclosed a quarterly dividend, which will be paid on Monday, October 31st. Stockholders of record on Friday, September 30th will be given a dividend of $0.38 per share. This represents a $1.52 dividend on an annualized basis and a dividend yield of 1.34%. The ex-dividend date of this dividend is Wednesday, September 28th. Stryker Corp.’s dividend payout ratio is presently 35.85%.

A number of research firms recently weighed in on SYK. Piper Jaffray Cos. upped their price objective on shares of Stryker Corp. from $120.00 to $135.00 and gave the stock an “overweight” rating in a research note on Friday, July 22nd. Credit Suisse Group AG reaffirmed an “outperform” rating and issued a $124.00 price objective (up from $110.00) on shares of Stryker Corp. in a research note on Tuesday, July 19th. Brean Capital reaffirmed a “buy” rating and issued a $125.00 price objective (up from $121.00) on shares of Stryker Corp. in a research note on Monday, July 25th. Jefferies Group reaffirmed a “hold” rating and issued a $120.00 price objective (up from $113.00) on shares of Stryker Corp. in a research note on Monday, July 25th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Stryker Corp. in a research note on Sunday, July 24th. Four analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $114.91.

Institutional investors have recently made changes to their positions in the company. Carroll Financial Associates Inc. boosted its stake in Stryker Corp. by 36.8% in the third quarter. Carroll Financial Associates Inc. now owns 1,486 shares of the medical technology company’s stock valued at $172,000 after buying an additional 400 shares during the last quarter. Cobiz Investment Management LLC boosted its stake in Stryker Corp. by 9.2% in the third quarter. Cobiz Investment Management LLC now owns 2,379 shares of the medical technology company’s stock valued at $277,000 after buying an additional 200 shares during the last quarter. Oregon Public Employees Retirement Fund boosted its stake in Stryker Corp. by 26.9% in the third quarter. Oregon Public Employees Retirement Fund now owns 85,178 shares of the medical technology company’s stock valued at $9,916,000 after buying an additional 18,034 shares during the last quarter. Advisory Services Network LLC boosted its stake in Stryker Corp. by 22.0% in the third quarter. Advisory Services Network LLC now owns 2,899 shares of the medical technology company’s stock valued at $337,000 after buying an additional 522 shares during the last quarter. Finally, Capital Investment Services of America Inc. boosted its stake in Stryker Corp. by 1.2% in the third quarter. Capital Investment Services of America Inc. now owns 100,050 shares of the medical technology company’s stock valued at $11,647,000 after buying an additional 1,175 shares during the last quarter. 75.49% of the stock is owned by institutional investors and hedge funds.

Stryker Corp. Company Profile

Stryker Corporation (Stryker) is a medical technology company. The Company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Company’s Orthopaedics segment products consist of implants used in hip and knee joint replacements and trauma and surgeries. The Company’s MedSurg segment products consist of surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical), and reprocessed and remanufactured medical devices (Sustainability), as well as other medical device products used in a range of medical specialties.

5 Day Chart for NYSE:SYK

Receive News & Stock Ratings for Stryker Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corp. and related stocks with our FREE daily email newsletter.